Literature DB >> 24652042

Epigenetics of multiple sclerosis: an updated review.

Cem İsmail Küçükali1, Murat Kürtüncü, Arzu Çoban, Merve Çebi, Erdem Tüzün.   

Abstract

Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease characterized with autoimmune response against myelin proteins and progressive axonal loss. The heterogeneity of the clinical course and low concordance rates in monozygotic twins have indicated the involvement of complex heritable and environmental factors in MS pathogenesis. MS is more often transmitted to the next generation by mothers than fathers suggesting an epigenetic influence. One of the possible reasons of this parent-of-origin effect might be the human leukocyte antigen-DRB1*15 allele, which is the major risk factor for MS and regulated by epigenetic mechanisms such as DNA methylation and histone deacetylation. Moreover, major environmental risk factors for MS, vitamin D deficiency, smoking and Ebstein-Barr virus are all known to exert epigenetic changes. In the last few decades, compelling evidence implicating the role of epigenetics in MS has accumulated. Increased or decreased acetylation, methylation and citrullination of genes regulating the expression of inflammation and myelination factors appear to be particularly involved in the epigenetics of MS. Although much less is known about epigenetic factors causing neurodegeneration, epigenetic mechanisms regulating axonal loss, apoptosis and mitochondrial dysfunction in MS are in the process of identification. Additionally, expression levels of several microRNAs (miRNAs) (e.g., miR-155 and miR-326) are increased in MS brains and potential mechanisms by which these factors might influence MS pathogenesis have been described. Certain miRNAs may also be potentially used as diagnostic biomarkers in MS. Several reagents, especially histone deacetylase inhibitors have been shown to ameliorate the symptoms of experimental allergic encephalomyelitis. Ongoing efforts in this field are expected to result in characterization of epigenetic factors that can be used in prediction of treatment responsive MS patients, diagnostic screening panels and treatment methods with specific mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24652042     DOI: 10.1007/s12017-014-8298-6

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  130 in total

1.  Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  B Richardson; L Scheinbart; J Strahler; L Gross; S Hanash; M Johnson
Journal:  Arthritis Rheum       Date:  1990-11

2.  HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells.

Authors:  Claire Jacob; Carlos N Christen; Jorge A Pereira; Christian Somandin; Arianna Baggiolini; Pirmin Lötscher; Murat Ozçelik; Nicolas Tricaud; Dies Meijer; Teppei Yamaguchi; Patrick Matthias; Ueli Suter
Journal:  Nat Neurosci       Date:  2011-03-20       Impact factor: 24.884

3.  The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression.

Authors:  Bin Liu; Samuel Tahk; Kathleen M Yee; Guoping Fan; Ke Shuai
Journal:  Science       Date:  2010-10-22       Impact factor: 47.728

4.  Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression.

Authors:  Anne-Sophie Korganow; Anne-Marie Knapp; Hélène Nehme-Schuster; Pauline Soulas-Sprauel; Vincent Poindron; Jean-Louis Pasquali; Thierry Martin
Journal:  J Autoimmun       Date:  2009-12-05       Impact factor: 7.094

5.  Parent-of-origin effect in multiple sclerosis: observations in half-siblings.

Authors:  G C Ebers; A D Sadovnick; D A Dyment; I M L Yee; C J Willer; Neil Risch
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

Review 6.  DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients.

Authors:  Ying Zhou; Qianjin Lu
Journal:  Autoimmun Rev       Date:  2008-04-04       Impact factor: 9.754

7.  Demethylation of CD40LG on the inactive X in T cells from women with lupus.

Authors:  Qianjin Lu; Ailing Wu; Laura Tesmer; Donna Ray; Neda Yousif; Bruce Richardson
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

8.  Abnormal histone modification patterns in lupus CD4+ T cells.

Authors:  Nan Hu; Xiangning Qiu; Yongqi Luo; Jun Yuan; Yaping Li; Wenzhi Lei; Guiying Zhang; Ying Zhou; Yuwen Su; Qianjin Lu
Journal:  J Rheumatol       Date:  2008-04-01       Impact factor: 4.666

9.  Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Authors:  Anne Waschbisch; Monika Atiya; Ralf A Linker; Sergej Potapov; Stefan Schwab; Tobias Derfuss
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

10.  Differential micro RNA expression in PBMC from multiple sclerosis patients.

Authors:  David Otaegui; Sergio E Baranzini; Ruben Armañanzas; Borja Calvo; Maider Muñoz-Culla; Puya Khankhanian; Iñaki Inza; Jose A Lozano; Tamara Castillo-Triviño; Ana Asensio; Javier Olaskoaga; Adolfo López de Munain
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more
  33 in total

Review 1.  Recent progress on cheminformatics approaches to epigenetic drug discovery.

Authors:  Zoe Sessions; Norberto Sánchez-Cruz; Fernando D Prieto-Martínez; Vinicius M Alves; Hudson P Santos; Eugene Muratov; Alexander Tropsha; José L Medina-Franco
Journal:  Drug Discov Today       Date:  2020-09-30       Impact factor: 7.851

Review 2.  Multiple sclerosis in men: management considerations.

Authors:  Riley Bove; Allison McHenry; Kerstin Hellwig; Maria Houtchens; Neda Razaz; Penelope Smyth; Helen Tremlett; A D Sadovnick; D Rintell
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 3.  Critical Link Between Epigenetics and Transcription Factors in the Induction of Autoimmunity: a Comprehensive Review.

Authors:  Haijing Wu; Ming Zhao; Akihiko Yoshimura; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

4.  Differential upregulation of the hypothetical transmembrane protein 66 (TMEM66) in multiple sclerosis patients with potential inflammatory response.

Authors:  Safa Taha; Muna Aljishi; Isa Alsharoqi; Moiz Bakhiet
Journal:  Biomed Rep       Date:  2014-11-17

Review 5.  Management of women with multiple sclerosis through pregnancy and after childbirth.

Authors:  Patricia K Coyle
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

6.  Expression analysis of long non-coding RNAs and their target genes in multiple sclerosis patients.

Authors:  Maziar Ganji; Arezou Sayad; Mir Davood Omrani; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2019-01-24       Impact factor: 3.307

Review 7.  DNA Methylation: a New Player in Multiple Sclerosis.

Authors:  Xiang Li; Bing Xiao; Xing-Shu Chen
Journal:  Mol Neurobiol       Date:  2016-06-17       Impact factor: 5.590

8.  Adoptive transfer of immunomodulatory M2 macrophages suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice via blockading NF-κB pathway.

Authors:  F Chu; M Shi; Y Lang; Z Chao; T Jin; L Cui; J Zhu
Journal:  Clin Exp Immunol       Date:  2021-02-01       Impact factor: 4.330

9.  Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.

Authors:  Deidre J Devier; Jesus F Lovera; Walter J Lukiw
Journal:  Front Mol Neurosci       Date:  2015-03-02       Impact factor: 5.639

10.  The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus.

Authors:  Yang Liu; Guangqiang Gao; Chun Yang; Kun Zhou; Baozhong Shen; Hongyan Liang; Xiaofeng Jiang
Journal:  Int J Mol Sci       Date:  2014-06-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.